Ovarian Epithelial Cancer  >>  pegylated liposomal doxorubicin  >>  Phase 1
Welcome,         Profile    Billing    Logout  

12 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pegylated liposomal doxorubicin / Generic mfg.
NCT00770536: AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Checkmark In combination with PLD/topotecan in women with recurrent/platinum-resistant/partially platinum-sensitive ovarian cancer
Jul 2014 - Jul 2014: In combination with PLD/topotecan in women with recurrent/platinum-resistant/partially platinum-sensitive ovarian cancer
Completed
1b
103
US, Europe, RoW
A1: AMG 386 10 mg/kg + Liposomal doxorubicin, Liposomal doxorubicin, AMG 386, A3: AMG 386 15mg/kg + Liposomal doxorubicin, B1: AMG 386 10 mg/kg + Topotecan, Topotecan, B3: AMG 386 15mg/kg + Topotecan
Amgen
Cancer, Carcinoma, Fallopian Tube Cancer, Gynecological Malignancies, Metastases, Oncology, Ovarian Cancer, Solid Tumors, Tumors
01/12
06/15
NCT00003380: Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Terminated
1
US, Canada
etoposide, pegylated liposomal doxorubicin hydrochloride
Gynecologic Oncology Group, National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
07/02
 
NCT00006235: Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed
1
US
carboplatin, pegylated liposomal doxorubicin hydrochloride
Gynecologic Oncology Group, National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
02/06
 
NCT00003385: Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer

Completed
1
48
US, Europe
carboplatin, paclitaxel, pegylated liposomal doxorubicin hydrochloride
Gynecologic Oncology Group, National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
01/07
 
NCT00659178: Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer

Completed
1
15
US
SB-485232 (interleukin 18), pegylated liposomal doxorubicin, SB-485232 (interleukin 18), pegylated liposomal doxorubicin
GlaxoSmithKline
Neoplasms, Ovarian
02/11
02/11
NCT01202890: Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

Terminated
1
1
US
Lenalidomide, Liposomal Doxorubicin, Bevacizumab, Revlimid, Doxil, Avastin
New Mexico Cancer Care Alliance, Celgene Corporation
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
05/11
05/12
MORAb-003-005, NCT01004380: Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

Completed
1
15
US
Farletuzumab, Carboplatin, and PLD, Farletuzumab (MORAb-003), Carboplatin, PLD
Morphotek
Epithelial Ovarian Cancer
08/12
10/12
NCT01329549: Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)

Terminated
1
2
Japan
BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Boehringer Ingelheim
Ovarian Neoplasms
10/12
10/12
NCT01314105: BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Completed
1
19
Europe
BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Boehringer Ingelheim
Ovarian Neoplasms, Peritoneal Neoplasms
07/13
04/16
NCT01294293: TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Completed
1
20
US
TLR8 Agonist VTX-2337, Toll-like Receptor 8 Agonist VTX-2337, VTX-2337, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, pharmacological studies, Pegylated Liposomal Doxorubicin Hydrochloride, doxorubicin HCl liposome, TLC D-99, Paclitaxel, Anzatax, TAX
Gynecologic Oncology Group, National Cancer Institute (NCI)
Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Ovarian Carcinoma
07/14
 
NCT01489371: EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Completed
1
16
US
Laboratory Biomarker Analysis, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1, GEN-1, IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer, Nanoparticle-encased IL-12 DNA Plasmid Vector, phIL-12-005, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, DOX-SL, Doxil, Doxilen, Doxorubicin HCl Liposome, doxorubicin hydrochloride liposome, Duomeisu, Evacet, LipoDox, Liposomal Adriamycin, liposomal doxorubicin hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99
Gynecologic Oncology Group, National Cancer Institute (NCI)
Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
12/14
01/18
NCT01145430: Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
1
45
US
Laboratory Biomarker Analysis, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, DOX-SL, Doxil, Doxilen, Doxorubicin HCl Liposome, doxorubicin hydrochloride liposome, Duomeisu, Evacet, LipoDox, Liposomal Adriamycin, liposomal doxorubicin hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Pharmacological Study, Veliparib, ABT-888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
05/17
 

Download Options